Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase i trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors

Robert J. Morgan, Timothy Synold, Adam Mamelak, Dean Lim, Zaid Al-Kadhimi, Przemyslaw Twardowski, Lucille Leong, Warren Chow, Kim Margolin, Stephen Shibata, George Somlo, Yun Yen, Paul Frankel, James H. Doroshow

研究成果: 雜誌貢獻文章

6 引文 (Scopus)

摘要

Purpose: This study was designed to ascertain the dose-limiting toxicities (DLT) and maximally tolerated doses of the combination of fixed-dose tamoxifen and carboplatin, with escalating doses of topotecan, and to determine the pharmacokinetics of topotecan in the plasma and cerebrospinal fluid. Methods: Tamoxifen 100 mg po bid, topotecan 0.25, 0.5, 0.75, or 1.0 mg/m2/d IV, administered as a 72 h continuous infusion on days 1-3, followed by carboplatin AUC = 3, IV on day 3. Cycles were repeated every 4 weeks. Results: Seventeen patients received 39 cycles of treatment: median 2, (range 1-5). The tumors included glioblastoma (6), anaplastic astrocytoma (2), metastatic non-small cell (3), small cell lung (2), and one each with medulloblastoma, ependymoma, and metastatic breast or colon carcinoma. The median Karnofsky performance status was 70% (range 60-90%) and age: 52 (range 24-75). Eleven patients were female and six male. Toxicities included thrombocytopenia (2), neutropenia without fever lasting 6 days (1), DVT (2), and emesis (1). Topotecan levels, total and lactone, were measured prior to the end of infusion in plasma and cerebrospinal fluid (CSF). At 1.0 mg/m2/d, the median CSF/plasma ratio was 19.4% (range 15.1-59.1%). The total plasma topotecan in two pts with DLTs was 4.63 and 5.87 ng/ml, in three without DLTs at the same dose level the mean total plasma topotecan was 3.4 ng/ml (range 3.02-3.83). Plasma lactone levels were 33% of the total; CSF penetration was 20% of the total plasma levels. 4/8 pts with high-grade gliomas had stable disease (median: 3 cycles (range 2-5)). Two had minor responses. One patient with metastatic non-small cell and one with small cell lung cancer had objective PRs. Conclusions: The recommended phase II doses are: tamoxifen 100 mg po bid, topotecan 0.75 mg/m2/d IV continuous infusion for 72 h, followed by carboplatin AUC = 3 IV on day 3. Measurable topotecan levels, both total and lactone, are observed in the CSF.

原文英語
頁(從 - 到)927-933
頁數7
期刊Cancer Chemotherapy and Pharmacology
66
發行號5
DOIs
出版狀態已發佈 - 十月 1 2010
對外發佈Yes

指紋

Spinal Cord Neoplasms
Topotecan
Cerebrospinal fluid
Pharmacokinetics
Carboplatin
Tamoxifen
Refractory materials
Cerebrospinal Fluid
Tumors
Brain
Plasmas
Lactones
Therapeutics
Area Under Curve
Toxicity
Cells
Karnofsky Performance Status
Ependymoma
Medulloblastoma
Maximum Tolerated Dose

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

引用此文

Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase i trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. / Morgan, Robert J.; Synold, Timothy; Mamelak, Adam; Lim, Dean; Al-Kadhimi, Zaid; Twardowski, Przemyslaw; Leong, Lucille; Chow, Warren; Margolin, Kim; Shibata, Stephen; Somlo, George; Yen, Yun; Frankel, Paul; Doroshow, James H.

於: Cancer Chemotherapy and Pharmacology, 卷 66, 編號 5, 01.10.2010, p. 927-933.

研究成果: 雜誌貢獻文章

Morgan, RJ, Synold, T, Mamelak, A, Lim, D, Al-Kadhimi, Z, Twardowski, P, Leong, L, Chow, W, Margolin, K, Shibata, S, Somlo, G, Yen, Y, Frankel, P & Doroshow, JH 2010, 'Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase i trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors', Cancer Chemotherapy and Pharmacology, 卷 66, 編號 5, 頁 927-933. https://doi.org/10.1007/s00280-010-1242-z
Morgan, Robert J. ; Synold, Timothy ; Mamelak, Adam ; Lim, Dean ; Al-Kadhimi, Zaid ; Twardowski, Przemyslaw ; Leong, Lucille ; Chow, Warren ; Margolin, Kim ; Shibata, Stephen ; Somlo, George ; Yen, Yun ; Frankel, Paul ; Doroshow, James H. / Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase i trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. 於: Cancer Chemotherapy and Pharmacology. 2010 ; 卷 66, 編號 5. 頁 927-933.
@article{cfb9b31c6e14459b995465b0b6b1fe53,
title = "Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase i trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors",
abstract = "Purpose: This study was designed to ascertain the dose-limiting toxicities (DLT) and maximally tolerated doses of the combination of fixed-dose tamoxifen and carboplatin, with escalating doses of topotecan, and to determine the pharmacokinetics of topotecan in the plasma and cerebrospinal fluid. Methods: Tamoxifen 100 mg po bid, topotecan 0.25, 0.5, 0.75, or 1.0 mg/m2/d IV, administered as a 72 h continuous infusion on days 1-3, followed by carboplatin AUC = 3, IV on day 3. Cycles were repeated every 4 weeks. Results: Seventeen patients received 39 cycles of treatment: median 2, (range 1-5). The tumors included glioblastoma (6), anaplastic astrocytoma (2), metastatic non-small cell (3), small cell lung (2), and one each with medulloblastoma, ependymoma, and metastatic breast or colon carcinoma. The median Karnofsky performance status was 70{\%} (range 60-90{\%}) and age: 52 (range 24-75). Eleven patients were female and six male. Toxicities included thrombocytopenia (2), neutropenia without fever lasting 6 days (1), DVT (2), and emesis (1). Topotecan levels, total and lactone, were measured prior to the end of infusion in plasma and cerebrospinal fluid (CSF). At 1.0 mg/m2/d, the median CSF/plasma ratio was 19.4{\%} (range 15.1-59.1{\%}). The total plasma topotecan in two pts with DLTs was 4.63 and 5.87 ng/ml, in three without DLTs at the same dose level the mean total plasma topotecan was 3.4 ng/ml (range 3.02-3.83). Plasma lactone levels were 33{\%} of the total; CSF penetration was 20{\%} of the total plasma levels. 4/8 pts with high-grade gliomas had stable disease (median: 3 cycles (range 2-5)). Two had minor responses. One patient with metastatic non-small cell and one with small cell lung cancer had objective PRs. Conclusions: The recommended phase II doses are: tamoxifen 100 mg po bid, topotecan 0.75 mg/m2/d IV continuous infusion for 72 h, followed by carboplatin AUC = 3 IV on day 3. Measurable topotecan levels, both total and lactone, are observed in the CSF.",
keywords = "Brain tumors, Carboplatin, Chemotherapy, Tamoxifen, Topotecan",
author = "Morgan, {Robert J.} and Timothy Synold and Adam Mamelak and Dean Lim and Zaid Al-Kadhimi and Przemyslaw Twardowski and Lucille Leong and Warren Chow and Kim Margolin and Stephen Shibata and George Somlo and Yun Yen and Paul Frankel and Doroshow, {James H.}",
year = "2010",
month = "10",
day = "1",
doi = "10.1007/s00280-010-1242-z",
language = "English",
volume = "66",
pages = "927--933",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase i trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors

AU - Morgan, Robert J.

AU - Synold, Timothy

AU - Mamelak, Adam

AU - Lim, Dean

AU - Al-Kadhimi, Zaid

AU - Twardowski, Przemyslaw

AU - Leong, Lucille

AU - Chow, Warren

AU - Margolin, Kim

AU - Shibata, Stephen

AU - Somlo, George

AU - Yen, Yun

AU - Frankel, Paul

AU - Doroshow, James H.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Purpose: This study was designed to ascertain the dose-limiting toxicities (DLT) and maximally tolerated doses of the combination of fixed-dose tamoxifen and carboplatin, with escalating doses of topotecan, and to determine the pharmacokinetics of topotecan in the plasma and cerebrospinal fluid. Methods: Tamoxifen 100 mg po bid, topotecan 0.25, 0.5, 0.75, or 1.0 mg/m2/d IV, administered as a 72 h continuous infusion on days 1-3, followed by carboplatin AUC = 3, IV on day 3. Cycles were repeated every 4 weeks. Results: Seventeen patients received 39 cycles of treatment: median 2, (range 1-5). The tumors included glioblastoma (6), anaplastic astrocytoma (2), metastatic non-small cell (3), small cell lung (2), and one each with medulloblastoma, ependymoma, and metastatic breast or colon carcinoma. The median Karnofsky performance status was 70% (range 60-90%) and age: 52 (range 24-75). Eleven patients were female and six male. Toxicities included thrombocytopenia (2), neutropenia without fever lasting 6 days (1), DVT (2), and emesis (1). Topotecan levels, total and lactone, were measured prior to the end of infusion in plasma and cerebrospinal fluid (CSF). At 1.0 mg/m2/d, the median CSF/plasma ratio was 19.4% (range 15.1-59.1%). The total plasma topotecan in two pts with DLTs was 4.63 and 5.87 ng/ml, in three without DLTs at the same dose level the mean total plasma topotecan was 3.4 ng/ml (range 3.02-3.83). Plasma lactone levels were 33% of the total; CSF penetration was 20% of the total plasma levels. 4/8 pts with high-grade gliomas had stable disease (median: 3 cycles (range 2-5)). Two had minor responses. One patient with metastatic non-small cell and one with small cell lung cancer had objective PRs. Conclusions: The recommended phase II doses are: tamoxifen 100 mg po bid, topotecan 0.75 mg/m2/d IV continuous infusion for 72 h, followed by carboplatin AUC = 3 IV on day 3. Measurable topotecan levels, both total and lactone, are observed in the CSF.

AB - Purpose: This study was designed to ascertain the dose-limiting toxicities (DLT) and maximally tolerated doses of the combination of fixed-dose tamoxifen and carboplatin, with escalating doses of topotecan, and to determine the pharmacokinetics of topotecan in the plasma and cerebrospinal fluid. Methods: Tamoxifen 100 mg po bid, topotecan 0.25, 0.5, 0.75, or 1.0 mg/m2/d IV, administered as a 72 h continuous infusion on days 1-3, followed by carboplatin AUC = 3, IV on day 3. Cycles were repeated every 4 weeks. Results: Seventeen patients received 39 cycles of treatment: median 2, (range 1-5). The tumors included glioblastoma (6), anaplastic astrocytoma (2), metastatic non-small cell (3), small cell lung (2), and one each with medulloblastoma, ependymoma, and metastatic breast or colon carcinoma. The median Karnofsky performance status was 70% (range 60-90%) and age: 52 (range 24-75). Eleven patients were female and six male. Toxicities included thrombocytopenia (2), neutropenia without fever lasting 6 days (1), DVT (2), and emesis (1). Topotecan levels, total and lactone, were measured prior to the end of infusion in plasma and cerebrospinal fluid (CSF). At 1.0 mg/m2/d, the median CSF/plasma ratio was 19.4% (range 15.1-59.1%). The total plasma topotecan in two pts with DLTs was 4.63 and 5.87 ng/ml, in three without DLTs at the same dose level the mean total plasma topotecan was 3.4 ng/ml (range 3.02-3.83). Plasma lactone levels were 33% of the total; CSF penetration was 20% of the total plasma levels. 4/8 pts with high-grade gliomas had stable disease (median: 3 cycles (range 2-5)). Two had minor responses. One patient with metastatic non-small cell and one with small cell lung cancer had objective PRs. Conclusions: The recommended phase II doses are: tamoxifen 100 mg po bid, topotecan 0.75 mg/m2/d IV continuous infusion for 72 h, followed by carboplatin AUC = 3 IV on day 3. Measurable topotecan levels, both total and lactone, are observed in the CSF.

KW - Brain tumors

KW - Carboplatin

KW - Chemotherapy

KW - Tamoxifen

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=77956230255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956230255&partnerID=8YFLogxK

U2 - 10.1007/s00280-010-1242-z

DO - 10.1007/s00280-010-1242-z

M3 - Article

C2 - 20107803

AN - SCOPUS:77956230255

VL - 66

SP - 927

EP - 933

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -